MELANOMA VACCINE--TYROSINASE/GP100 W/ MONTANIDE ISA51 OR GM CSF

黑色素瘤疫苗 - 酪氨酸酶/GP100 W/ Montanide ISA51 或 GM CSF

• 批准号: 6303499
• 负责人: VERNON K. SONDAK
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303499
• 关键词: cellular immunity; clinical research; colony stimulating factor; combination cancer therapy; enzyme linked immunosorbent assay; enzyme therapy; glycoproteins; human subject; human therapy evaluation; immunologic skin test; melanoma; monophenol monooxygenase; neoplasm /cancer immunotherapy; neoplasm /cancer vaccine; synthetic vaccines

In nonmalignant conditions, vaccines are not used to treat established disease, but rather to prevent disease from occurring in the first place. We believe that the best way to use vaccines to treat cancers like melanoma is to prevent disease from reoccurring after surgical treatment. We are studying the use of a peptide (protein fragment) vaccine that uses fragments of two proteins known to be on most melanoma cells. The fragments are known to be recognized by immune cells of patients who tissue type (similar to a blood type, also called HLA type) is HLA-A2+. In our study, patients with melanoma of the skin that has not spread to the lymph nodes but is thick enough to be concerning for reoccurrence (stage II melanoma) who are HLA-A2+ are given either the basic peptide vaccine or the vaccine plus GM-CSF injections. GM-CSF is a protein that stimulates the immune system and may improve the effectiveness of the vaccine, but the need for self-injections means that we don+t wish to use it unless it clearly improves the immune response to our vaccine. Injections are spread over a total of 6 months. Before and after vaccination, patients will have white blood cells removed by a procedure known as apheresis. The ability of these white cells to recognize and respond to the peptides before and after vaccination will be compared.

在非恶性条件下，疫苗不用于治疗已建立的疾病，而是首先是为了防止疾病发生。我们认为，使用疫苗治疗癌症等癌症的最佳方法是防止手术治疗后疾病再次发生。我们正在研究使用肽（蛋白质片段）疫苗的使用，该疫苗使用了大多数黑色素瘤细胞上已知的两种蛋白质的片段。已知这些片段被组织类型的患者的免疫细胞（类似于血型，也称为HLA类型）识别为HLA-A2+。在我们的研究中，尚未扩散到淋巴结的皮肤黑色素瘤的患者厚度足以使HLA-A2+的再发生（II期黑素瘤）有关，它们是基本的肽疫苗或疫苗疫苗或GM-CSF注射。 GM-CSF是一种刺激免疫系统并可能提高疫苗有效性的蛋白质，但是自我注射的需求意味着我们不希望使用它，除非它明确改善了对疫苗的免疫反应。注射分布在总计6个月内。疫苗接种前后，患者将通过称为置换术的手术去除白细胞。这些白细胞在疫苗接种前后对肽识别和反应的能力将被比较。